Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label prophylaxis with garadacimab (CSL312) in hereditary angioedema
jRCT2031210328Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Limited. Primary endpoints: Number of subjects with treatment-emergent adverse events (TEAEs), Percentage of subjects with TEAEs and 2 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031210328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210328.